Challenges in diagnosis and treatment of sporadic inclusion-body myositis

被引:0
|
作者
Sebastian, Agata [1 ]
Misterska-Skora, Maria [1 ]
Sebastian, Maciej [2 ]
Krecichwost, Roksana [3 ]
Haczkiewicz, Katarzyna [4 ]
机构
[1] Wroclaw Med Univ, Fac Med, Dept Rheumatol & Internal Med, Wroclaw, Poland
[2] Wroclaw Med Univ, Fac Med, Dept Minimally Invas Surg & Proctol, Wroclaw, Poland
[3] Wroclaw Med Univ, Fac Med, Dept Ophthalmol, Wroclaw, Poland
[4] Wroclaw Med Univ, Fac Med, Dept Histol & Embryol, Wroclaw, Poland
来源
基金
英国医学研究理事会;
关键词
biomarker; early diagnosis; sporadic inclusion body myositis; IDIOPATHIC INFLAMMATORY MYOPATHIES; SKELETAL-MUSCLES; RIMMED VACUOLES; EXPRESSION; AUTOANTIBODIES; ALEMTUZUMAB; PROTEINS; UPDATE; PHASE; CELLS;
D O I
10.17219/acem/69855
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Sporadic inclusion body myositis (sIBM) is a rare yet increasingly prevalent disease and the most common cause of inflammatory myopathy in people over the age of 50. The exact cause of the disorder is unknown. In sIBM 2 processes, first autoimmune and the other degenerative, parallelly occur in the muscle cells. The inflammation aspect is characterized by the cloning of T cells that appear to be driven by specific antigens to invade muscle fibers. The degeneration aspect is characterized by the appearance of holes in the muscle cell vacuoles, deposits of abnormal proteins within the cells and in filamentous inclusions. The disease has a major impact on patients' motor functionality and their quality of life. The treatment of sIBM still remains a major challenge. Early diagnosis of sIBM (already at the histopathology stage), when one still cannot observe fully developed clinical symptoms, may stop help to the progression of the disease.
引用
收藏
页码:1453 / 1457
页数:5
相关论文
共 50 条
  • [41] INCLUSION-BODY MYOSITIS - NEWEST ADVANCES
    ASKANAS, V
    ENGEL, WK
    BRAIN PATHOLOGY, 1994, 4 (04) : 361 - 362
  • [42] Polymyositis, dermatomyositis and inclusion-body myositis
    Jurjevic, Ante
    Bucuk, Mira
    ACTA NEUROPSYCHIATRICA, 2008, 20 : 14 - 15
  • [43] Mitochondrial abnormalities in inclusion-body myositis
    Oldfors, A
    Moslemi, AR
    Jonasson, L
    Ohlsson, M
    Kollberg, G
    Lindberg, C
    NEUROLOGY, 2006, 66 : S49 - S55
  • [44] INCLUSION-BODY MYOSITIS - NEW CONCEPTS
    SEKUL, EA
    DALAKAS, MC
    SEMINARS IN NEUROLOGY, 1993, 13 (03) : 256 - 263
  • [45] MTDNA DELETIONS IN MUSCLE OF SPORADIC INCLUSION-BODY MYOSITIS (S-IBM) AND HEREDITARY INCLUSION-BODY MHYOPATHY (H-IBM)
    PAQUIS, V
    PAUL, R
    ASKANAS, V
    ENGEL, WK
    DESNUELLE, C
    NEUROLOGY, 1995, 45 (04) : A445 - A445
  • [46] SUBCUTANEOUS IMMUNOGLOBULIN TREATMENT OF INCLUSION-BODY MYOSITIS STABILIZES DYSPHAGIA
    Pars, Kaweh
    Garde, Niklas
    Skripuletz, Thomas
    Pul, Refik
    Dengler, Reinhard
    Stangel, Martin
    MUSCLE & NERVE, 2013, 48 (05) : 838 - 839
  • [47] Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis
    Lowes, Linda Pax
    Alfano, Lindsay
    Viollet, Laurence
    Rosales, Xiomara Quintero
    Sahenk, Zarife
    Kaspar, Brian K.
    Clark, K. Reed
    Flanigan, Kevin M.
    Mendell, Jerry R.
    McDermott, Michael P.
    MUSCLE & NERVE, 2012, 45 (02) : 163 - 168
  • [48] Dysphagia in Patients with Sporadic Inclusion Body Myositis: Management Challenges
    Mohannak, Nika
    Pattison, Gemma
    Hird, Kathryn
    Needham, Merrilee
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2019, 12 : 465 - 474
  • [49] Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers
    Anna Nogalska
    Carla D’Agostino
    W. King Engel
    William L. Klein
    Valerie Askanas
    Acta Neuropathologica, 2010, 120 : 661 - 666
  • [50] Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers
    Nogalska, Anna
    D'Agostino, Carla
    Engel, W. King
    Klein, William L.
    Askanas, Valerie
    ACTA NEUROPATHOLOGICA, 2010, 120 (05) : 661 - 666